| 1 | Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer | 3.5 | 2 | Citations (PDF) |
| 2 | The potential benefits of concomitant statins treatment in <scp>patients with non‐muscle‐invasive bladder cancer</scp> | 3.5 | 1 | Citations (PDF) |
| 3 | Impact of the extent of lymph node dissection on survival outcomes in clinically lymph <scp>node‐positive</scp> bladder cancer | 3.5 | 8 | Citations (PDF) |
| 4 | Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials | 1.9 | 2 | Citations (PDF) |
| 5 | The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer | 14.1 | 5 | Citations (PDF) |
| 6 | Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry | 4.0 | 0 | Citations (PDF) |
| 7 | The optimal number of induction chemotherapy cycles in clinically lymph node‐positive bladder cancer | 3.5 | 2 | Citations (PDF) |
| 8 | Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer | 0.2 | 1 | Citations (PDF) |
| 9 | Mitochondrial complex I promotes kidney cancer metastasis | 40.1 | 15 | Citations (PDF) |
| 10 | The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis | 1.0 | 1 | Citations (PDF) |
| 11 | Early experience with UGN-101 for the treatment of upper tract urothelial cancer – A multicenter evaluation of practice patterns and outcomes | 1.9 | 6 | Citations (PDF) |
| 12 | Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy | 3.5 | 37 | Citations (PDF) |
| 13 | Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction | 6.4 | 6 | Citations (PDF) |
| 14 | Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy | 1.9 | 9 | Citations (PDF) |
| 15 | Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer | 4.4 | 17 | Citations (PDF) |
| 16 | Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System | 4.4 | 7 | Citations (PDF) |
| 17 | The early impact of medicaid expansion on urologic malignancies in the United States | 1.9 | 4 | Citations (PDF) |
| 18 | Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons | 4.4 | 9 | Citations (PDF) |
| 19 | Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy | 4.4 | 41 | Citations (PDF) |
| 20 | Role of blue‐light cystoscopy in detecting invasive bladder tumours: data from a multi‐institutional registry | 3.5 | 7 | Citations (PDF) |
| 21 | Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer | 2.4 | 3 | Citations (PDF) |
| 22 | The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy | 3.7 | 5 | Citations (PDF) |
| 23 | Corrigendum to “Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis” [Eur Urol Oncol 2021;4:927–42] | 5.8 | 2 | Citations (PDF) |
| 24 | Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer | 2.7 | 2 | Citations (PDF) |
| 25 | TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells | 5.8 | 46 | Citations (PDF) |
| 26 | Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series | 0.6 | 6 | Citations (PDF) |
| 27 | Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients | 1.9 | 26 | Citations (PDF) |
| 28 | Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy | 1.7 | 6 | Citations (PDF) |
| 29 | Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial | 1.4 | 18 | Citations (PDF) |
| 30 | Prognostic impact of insulin‐like growth factor‐I and its binding proteins, insulin‐like growth factor‐I binding protein‐2 and ‐3, on adverse histopathological features and survival outcomes after radical cystectomy | 1.7 | 4 | Citations (PDF) |
| 31 | Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients | 1.9 | 4 | Citations (PDF) |
| 32 | International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer | 1.4 | 50 | Citations (PDF) |
| 33 | Progress in the development of tissue-based biomarkers for urothelial cancer | 2.6 | 1 | Citations (PDF) |
| 34 | Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery | 3.0 | 5 | Citations (PDF) |
| 35 | Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration | 0.5 | 2 | Citations (PDF) |
| 36 | Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer | 3.5 | 4 | Citations (PDF) |
| 37 | Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study | 1.9 | 4 | Citations (PDF) |
| 38 | Impact of circulating microRNA test (miRNA‐371a‐3p) on appropriateness of treatment and cost outcomes in patients with Stage I non‐seminomatous germ cell tumours | 3.5 | 15 | Citations (PDF) |
| 39 | Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis | 3.5 | 11 | Citations (PDF) |
| 40 | Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample | 3.5 | 15 | Citations (PDF) |
| 41 | Robotic Nephroureterectomy <i>vs</i> Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically | 3.0 | 22 | Citations (PDF) |
| 42 | Prospective evaluation of blue‐light flexible cystoscopy with hexaminolevulinate in non‐muscle‐invasive bladder cancer | 3.5 | 12 | Citations (PDF) |
| 43 | Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma | 3.5 | 11 | Citations (PDF) |
| 44 | Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial | 21.9 | 254 | Citations (PDF) |
| 45 | Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria | 5.8 | 30 | Citations (PDF) |
| 46 | Value of tumour‐infiltrating immune cells in predicting response to intravesical BCG in patients with non‐muscle‐invasive bladder cancer: a systematic review and meta‐analysis | 3.5 | 15 | Citations (PDF) |
| 47 | Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts 2021, , 21-31 | | 0 | Citations (PDF) |
| 48 | Decision Analysis Model Comparing Cost of IsoPSA™ vs Repeat Biopsy for Detection of Clinically Significant Prostate Cancer in Men with Previous Negative Findings on Biopsy | 1.4 | 2 | Citations (PDF) |
| 49 | Bladder Cancer Tissue-Based Biomarkers | 0.2 | 1 | Citations (PDF) |
| 50 | Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management | 4.4 | 33 | Citations (PDF) |
| 51 | Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials | 0.5 | 2 | Citations (PDF) |
| 52 | Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer | 4.4 | 53 | Citations (PDF) |
| 53 | Reply by Authors | 4.4 | 1 | Citations (PDF) |
| 54 | MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer | 2.7 | 12 | Citations (PDF) |
| 55 | Simple Nephrectomy in a Tertiary Care Safety Net Hospital—Patient Characteristics, Causes, Cost, and Renal Function Implications | 1.5 | 2 | Citations (PDF) |
| 56 | Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence | 1.9 | 6 | Citations (PDF) |
| 57 | Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens | 1.7 | 4 | Citations (PDF) |
| 58 | Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection | 0.6 | 33 | Citations (PDF) |
| 59 | Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer | 4.7 | 7 | Citations (PDF) |
| 60 | Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert<sup>®</sup> Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer | 3.5 | 18 | Citations (PDF) |
| 61 | Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria | 4.4 | 16 | Citations (PDF) |
| 62 | Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection | 3.0 | 6 | Citations (PDF) |
| 63 | The Economics of Cystoscopy: A Microcost Analysis | 1.5 | 16 | Citations (PDF) |
| 64 | Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin | 6.4 | 90 | Citations (PDF) |
| 65 | Metabolic syndrome and bladder cancer | 3.5 | 6 | Citations (PDF) |
| 66 | Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy | 4.4 | 5 | Citations (PDF) |
| 67 | Metastasis-directed radiation therapy after radical cystectomy for bladder cancer | 1.9 | 13 | Citations (PDF) |
| 68 | Risk factors associated with positive surgical margins’ location at radical cystectomy and their impact on bladder cancer survival | 2.4 | 31 | Citations (PDF) |
| 69 | Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma | 1.9 | 19 | Citations (PDF) |
| 70 | Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab | 1.4 | 21 | Citations (PDF) |
| 71 | A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer | 0.5 | 5 | Citations (PDF) |
| 72 | Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer | 2.4 | 4 | Citations (PDF) |
| 73 | Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis | 4.0 | 45 | Citations (PDF) |
| 74 | Same Day Discharge Versus Overnight Observation Protocols – Similar Outcomes Following Artificial Urinary Sphincter Surgery | 1.5 | 3 | Citations (PDF) |
| 75 | Alternating Cystoscopy with Bladder EpiCheck<sup>®</sup> in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model | 0.5 | 3 | Citations (PDF) |
| 76 | The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma | 4.4 | 10 | Citations (PDF) |
| 77 | A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer | 0.7 | 27 | Citations (PDF) |
| 78 | Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition | 1.9 | 2 | Citations (PDF) |
| 79 | Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma | 1.4 | 2 | Citations (PDF) |
| 80 | Validation of testicular germ cell tumor staging in nationwide cancer registries | 1.9 | 3 | Citations (PDF) |
| 81 | Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis | 5.8 | 61 | Citations (PDF) |
| 82 | Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study | 4.0 | 5 | Citations (PDF) |
| 83 | Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle | 5.8 | 10 | Citations (PDF) |
| 84 | Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection | 1.4 | 58 | Citations (PDF) |
| 85 | The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy | 1.9 | 28 | Citations (PDF) |
| 86 | PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy | 1.9 | 7 | Citations (PDF) |
| 87 | Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy | 1.9 | 17 | Citations (PDF) |
| 88 | Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial | 2.6 | 19 | Citations (PDF) |
| 89 | Critical treatment choices for patients with platinum-refractory urothelial carcinoma | 21.9 | 2 | Citations (PDF) |
| 90 | Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis | 1.4 | 41 | Citations (PDF) |
| 91 | Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists | 1.9 | 8 | Citations (PDF) |
| 92 | Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma | 2.4 | 6 | Citations (PDF) |
| 93 | Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy? | 1.9 | 9 | Citations (PDF) |
| 94 | Initial Results from the M-STONE Group: A Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation | 3.0 | 6 | Citations (PDF) |
| 95 | Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital | 4.4 | 18 | Citations (PDF) |
| 96 | <p>The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States</p> | 1.9 | 3 | Citations (PDF) |
| 97 | Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors | 2.4 | 7 | Citations (PDF) |
| 98 | Office-Based Blue Light Flexible Cystoscopy Improves Diagnostic Capabilities | 0.1 | 0 | Citations (PDF) |
| 99 | Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma | 1.9 | 14 | Citations (PDF) |
| 100 | Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy | 1.9 | 12 | Citations (PDF) |
| 101 | Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer | 1.9 | 15 | Citations (PDF) |
| 102 | Novel technologies that change the diagnostic and treatment paradigm in urology | 2.1 | 1 | Citations (PDF) |
| 103 | Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database | 1.9 | 90 | Citations (PDF) |
| 104 | Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma | 2.6 | 5 | Citations (PDF) |
| 105 | Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences | 5.8 | 29 | Citations (PDF) |
| 106 | Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy | 2.4 | 4 | Citations (PDF) |
| 107 | A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging | 4.4 | 6 | Citations (PDF) |
| 108 | Microhematuria: AUA/SUFU Guideline | 4.4 | 160 | Citations (PDF) |
| 109 | Implementation of a Urology E-Consult Service at a Safety Net County Hospital | 1.4 | 5 | Citations (PDF) |
| 110 | Reply by Authors | 4.4 | 0 | Citations (PDF) |
| 111 | Financial Considerations in the Management of Small Renal Masses 2020, , 31-40 | | 0 | Citations (PDF) |
| 112 | Urinary-Based Markers for Bladder Cancer Detection | 0.2 | 3 | Citations (PDF) |
| 113 | Clinical Utility of Bladder Cancer Biomarkers | 0.2 | 2 | Citations (PDF) |
| 114 | Reply by Authors | 1.4 | 0 | Citations (PDF) |
| 115 | Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study | 3.5 | 16 | Citations (PDF) |
| 116 | Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes | 2.6 | 17 | Citations (PDF) |
| 117 | Current advances in BCG-unresponsive non-muscle invasive bladder cancer | 4.1 | 22 | Citations (PDF) |
| 118 | Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma | 1.9 | 22 | Citations (PDF) |
| 119 | Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer | 14.0 | 56 | Citations (PDF) |
| 120 | DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism | 2.9 | 10 | Citations (PDF) |
| 121 | Evaluation of Hematuria in a Large Public Health Care System | 0.5 | 22 | Citations (PDF) |
| 122 | Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis | 9.9 | 41 | Citations (PDF) |
| 123 | FP131COST ANALYSIS OF INCREASED WATER INTAKE ON RECURRENT CYSTITIS BASED ON RESULTS FROM A RANDOMIZED CLINICAL TRIAL | 0.8 | 0 | Citations (PDF) |
| 124 | Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy | 5.8 | 24 | Citations (PDF) |
| 125 | Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma | 2.3 | 15 | Citations (PDF) |
| 126 | Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy | 1.4 | 39 | Citations (PDF) |
| 127 | Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors | 1.4 | 41 | Citations (PDF) |
| 128 | Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018 | 3.9 | 58 | Citations (PDF) |
| 129 | Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer | 6.4 | 83 | Citations (PDF) |
| 130 | Delivery of Bottled Water to Women With Recurrent Urinary Tract Infections: Why in Bulgaria?—Reply | 8.9 | 0 | Citations (PDF) |
| 131 | Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder | 1.9 | 13 | Citations (PDF) |
| 132 | Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy | 21.9 | 4 | Citations (PDF) |
| 133 | Progress toward a Nordic standard for the investigation of hematuria: 2019 | 1.2 | 0 | Citations (PDF) |
| 134 | Molecular Characterization of Neuroendocrine-like Bladder Cancer | 6.4 | 73 | Citations (PDF) |
| 135 | Recent advances in the metabolomic study of bladder cancer | 2.2 | 28 | Citations (PDF) |
| 136 | Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts | 4.5 | 26 | Citations (PDF) |
| 137 | Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study | 2.4 | 6 | Citations (PDF) |
| 138 | Magnetic Resonance Imaging–guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate | 5.8 | 46 | Citations (PDF) |
| 139 | Is Cystoscopy a Major Source of Discomfort and Anxiety for Bladder Cancer Patients? | 0.7 | 0 | Citations (PDF) |
| 140 | Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer | 1.4 | 71 | Citations (PDF) |
| 141 | Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate | 4.5 | 19 | Citations (PDF) |
| 142 | Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy | 1.9 | 31 | Citations (PDF) |
| 143 | Validating the predictors of outcomes after radical cystectomy for bladder cancer | 4.4 | 30 | Citations (PDF) |
| 144 | Effect of blue‐light cystoscopy on contemporary performance of urine cytology | 3.5 | 11 | Citations (PDF) |
| 145 | Caveolin-1 Expression in Upper Tract Urothelial Carcinoma | 3.7 | 3 | Citations (PDF) |
| 146 | Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test | 3.7 | 5 | Citations (PDF) |
| 147 | Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression | 6.6 | 39 | Citations (PDF) |
| 148 | Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer | 4.4 | 15 | Citations (PDF) |
| 149 | Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial | 4.4 | 19 | Citations (PDF) |
| 150 | Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis | 4.4 | 19 | Citations (PDF) |
| 151 | Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI | 4.5 | 44 | Citations (PDF) |
| 152 | Re: Who Should be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients | 1.4 | 2 | Citations (PDF) |
| 153 | Modelling cost‐effectiveness of a biomarker‐based approach to neoadjuvant chemotherapy for muscle‐invasive bladder cancer | 3.5 | 14 | Citations (PDF) |
| 154 | Current approaches for identifying high-risk non-muscle invasive bladder cancer | 2.6 | 6 | Citations (PDF) |
| 155 | Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study | 4.4 | 82 | Citations (PDF) |
| 156 | Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses | 1.5 | 17 | Citations (PDF) |
| 157 | Reply by Authors | 1.4 | 0 | Citations (PDF) |
| 158 | Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer | 1.9 | 8 | Citations (PDF) |
| 159 | Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis | 1.9 | 25 | Citations (PDF) |
| 160 | Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood | 0.0 | 0 | Citations (PDF) |
| 161 | Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial | 2.4 | 11 | Citations (PDF) |
| 162 | Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures | 1.4 | 1 | Citations (PDF) |
| 163 | Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder | 3.7 | 42 | Citations (PDF) |
| 164 | Impact of hospital case volume on testicular cancer outcomes and practice patterns | 1.9 | 55 | Citations (PDF) |
| 165 | Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection | 4.4 | 55 | Citations (PDF) |
| 166 | Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States | 1.9 | 15 | Citations (PDF) |
| 167 | Impact of age on outcomes of patients with non–muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C | 1.9 | 7 | Citations (PDF) |
| 168 | Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi‐institution study | 3.5 | 13 | Citations (PDF) |
| 169 | Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018 | 1.4 | 563 | Citations (PDF) |
| 170 | Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections | 8.9 | 192 | Citations (PDF) |
| 171 | A Festschrift in Honor of Edward M. Messing, MD, FACS | 0.5 | 0 | Citations (PDF) |
| 172 | Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening | 1.9 | 0 | Citations (PDF) |
| 173 | Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer | 2.1 | 14 | Citations (PDF) |
| 174 | Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study | 2.4 | 15 | Citations (PDF) |
| 175 | Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort | 2.4 | 13 | Citations (PDF) |
| 176 | Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes | 5.8 | 16 | Citations (PDF) |
| 177 | Editorial Comment | 1.5 | 2 | Citations (PDF) |
| 178 | The Use of Blue Light Flexible Cystoscopy With Hexaminolevulinate & the Diagnosis of Bladder Cancer | 2.4 | 3 | Citations (PDF) |
| 179 | An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer | 2.4 | 100 | Citations (PDF) |
| 180 | Understanding concepts related to health economics in urology 2018, , 53-58 | | 0 | Citations (PDF) |
| 181 | Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma | 1.9 | 4 | Citations (PDF) |
| 182 | Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo | 26.3 | 196 | Citations (PDF) |
| 183 | Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review | 5.8 | 25 | Citations (PDF) |
| 184 | Molecular markers in bladder cancer | 2.4 | 89 | Citations (PDF) |
| 185 | Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer | 1.7 | 19 | Citations (PDF) |
| 186 | Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer | 1.7 | 8 | Citations (PDF) |
| 187 | Editorial response to “Clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study” | 1.3 | 0 | Citations (PDF) |
| 188 | Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi‐institutional study | 3.5 | 14 | Citations (PDF) |
| 189 | Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy | 1.4 | 11 | Citations (PDF) |
| 190 | Decision Analysis Model Comparing Cost of Management Strategies for Pelvic Fracture Urethral Injuries | 1.4 | 2 | Citations (PDF) |
| 191 | Guideline of guidelines: non‐muscle‐invasive bladder cancer | 3.5 | 199 | Citations (PDF) |
| 192 | Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma | 33.4 | 541 | Citations (PDF) |
| 193 | Prognostic value of tissue‐based biomarker signature in clear cell renal cell carcinoma | 3.5 | 15 | Citations (PDF) |
| 194 | The economics of stone disease | 2.4 | 31 | Citations (PDF) |
| 195 | Epidemiology of stone disease across the world | 2.4 | 617 | Citations (PDF) |
| 196 | Bladder cancer | 24.7 | 610 | Citations (PDF) |
| 197 | Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO‐IMPACT study | 4.4 | 63 | Citations (PDF) |
| 198 | Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance | 4.4 | 4 | Citations (PDF) |
| 199 | Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline | 4.4 | 707 | Citations (PDF) |
| 200 | Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer | 13.6 | 122 | Citations (PDF) |
| 201 | Lynch syndrome in upper tract urothelial carcinoma | 2.1 | 30 | Citations (PDF) |
| 202 | Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study | 2.4 | 14 | Citations (PDF) |
| 203 | Tackling non-muscle invasive bladder cancer in the clinic | 2.6 | 10 | Citations (PDF) |
| 204 | Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior | 3.7 | 38 | Citations (PDF) |
| 205 | Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma | 1.9 | 98 | Citations (PDF) |
| 206 | Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study | 4.4 | 83 | Citations (PDF) |
| 207 | An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer—Preliminary experience | 1.9 | 20 | Citations (PDF) |
| 208 | Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017, 171, 540-556.e25 | 35.1 | 1,678 | Citations (PDF) |
| 209 | Tissue-based biomarkers in prostate cancer | 0.9 | 20 | Citations (PDF) |
| 210 | Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy | 1.9 | 5 | Citations (PDF) |
| 211 | Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma | 2.4 | 14 | Citations (PDF) |
| 212 | Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy | 1.4 | 0 | Citations (PDF) |
| 213 | Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer | 2.8 | 59 | Citations (PDF) |
| 214 | Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials | 1.0 | 25 | Citations (PDF) |
| 215 | Editorial comment | 2.1 | 0 | Citations (PDF) |
| 216 | Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy | 4.4 | 4 | Citations (PDF) |
| 217 | Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma | 4.4 | 59 | Citations (PDF) |
| 218 | Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma | 4.4 | 33 | Citations (PDF) |
| 219 | Superior Cost Effectiveness of Penile Plication vs Intralesional Collagenase Injection for Treatment of Peyronie’s Disease Deformities | 1.4 | 21 | Citations (PDF) |
| 220 | A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States | 4.4 | 44 | Citations (PDF) |
| 221 | Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial | 2.6 | 16 | Citations (PDF) |
| 222 | Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women: A Prospective, Randomized, Controlled Study | 0.8 | 5 | Citations (PDF) |
| 223 | Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer | 1.7 | 43 | Citations (PDF) |
| 224 | Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer | 1.6 | 12 | Citations (PDF) |
| 225 | Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study | 17.1 | 134 | Citations (PDF) |
| 226 | Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary | 3.5 | 38 | Citations (PDF) |
| 227 | Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer | 1.3 | 25 | Citations (PDF) |
| 228 | Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer | 1.7 | 18 | Citations (PDF) |
| 229 | Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer | 1.1 | 10 | Citations (PDF) |
| 230 | Alternative therapies in patients with non-muscle invasive bladder cancer | 0.2 | 8 | Citations (PDF) |
| 231 | Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study | 0.5 | 8 | Citations (PDF) |
| 232 | Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer | 3.5 | 73 | Citations (PDF) |
| 233 | Long-term outcomes in a high-risk bladder cancer screening cohort | 3.5 | 17 | Citations (PDF) |
| 234 | Prognostic value of Caveolin‐1 in patients treated with radical prostatectomy: a multicentric validation study | 3.5 | 14 | Citations (PDF) |
| 235 | Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses | 3.0 | 17 | Citations (PDF) |
| 236 | Analysis of genetics to identify susceptibility to secondary malignancies in patients with bladder cancer | 3.5 | 1 | Citations (PDF) |
| 237 | Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial | 3.3 | 130 | Citations (PDF) |
| 238 | Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications | 1.9 | 30 | Citations (PDF) |
| 239 | Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Analysis from the National Cancer Data Base | 1.4 | 1 | Citations (PDF) |
| 240 | Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate‐specific antigen screening | 4.4 | 24 | Citations (PDF) |
| 241 | Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma | 1.5 | 13 | Citations (PDF) |
| 242 | Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence | 3.1 | 9 | Citations (PDF) |
| 243 | Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis | 1.9 | 26 | Citations (PDF) |
| 244 | Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder | 1.9 | 15 | Citations (PDF) |
| 245 | Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non–muscle-invasive high-grade bladder cancer | 1.9 | 16 | Citations (PDF) |
| 246 | Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy | 4.4 | 36 | Citations (PDF) |
| 247 | Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract | 1.5 | 15 | Citations (PDF) |
| 248 | Bladder cancer | 35.3 | 1,048 | Citations (PDF) |
| 249 | Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study | 1.9 | 36 | Citations (PDF) |
| 250 | Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer | 10.0 | 6 | Citations (PDF) |
| 251 | The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis | 3.7 | 36 | Citations (PDF) |
| 252 | Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients | 1.9 | 28 | Citations (PDF) |
| 253 | Should patients newly diagnosed with bladder cancer be screened for lung cancer? | 1.7 | 3 | Citations (PDF) |
| 254 | Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival | 4.4 | 33 | Citations (PDF) |
| 255 | Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial | 1.9 | 26 | Citations (PDF) |
| 256 | Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy | 1.9 | 24 | Citations (PDF) |
| 257 | Use of an Electronic Medical Record to Assess Patient-Reported Morbidity Following Ureteroscopy | 3.0 | 12 | Citations (PDF) |
| 258 | The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance | 4.4 | 16 | Citations (PDF) |
| 259 | The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis | 1.9 | 23 | Citations (PDF) |
| 260 | Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer | 2.1 | 70 | Citations (PDF) |
| 261 | Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma | 2.1 | 10 | Citations (PDF) |
| 262 | Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1? | 4.4 | 74 | Citations (PDF) |
| 263 | Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes | 1.4 | 469 | Citations (PDF) |
| 264 | A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy | 4.4 | 100 | Citations (PDF) |
| 265 | Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer | 4.4 | 26 | Citations (PDF) |
| 266 | HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC) | 2.4 | 37 | Citations (PDF) |
| 267 | Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer | 2.4 | 7 | Citations (PDF) |
| 268 | Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study | 2.4 | 24 | Citations (PDF) |
| 269 | The kidney stone and increased water intake trial in steel workers: results from a pilot study | 1.8 | 24 | Citations (PDF) |
| 270 | Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC) | 2.4 | 292 | Citations (PDF) |
| 271 | Reimbursement for Prostate Cancer Treatment 2016, , 367-374 | | 0 | Citations (PDF) |
| 272 | Cost‐Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension | 2.1 | 20 | Citations (PDF) |
| 273 | Economics of bladder cancer 2015, , 90-102 | | 0 | Citations (PDF) |
| 274 | Corrigendum to “Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort” [Eur Urol 2010;57:300–9] | 1.4 | 3 | Citations (PDF) |
| 275 | Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma | 1.9 | 26 | Citations (PDF) |
| 276 | Lynch Syndrome: A Primer for Urologists and Panel Recommendations | 4.4 | 65 | Citations (PDF) |
| 277 | We Should Screen Smokers for Bladder and Kidney Cancer | 3.7 | 1 | Citations (PDF) |
| 278 | Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer | 1.4 | 240 | Citations (PDF) |
| 279 | Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma | 1.4 | 78 | Citations (PDF) |
| 280 | Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer | 0.9 | 16 | Citations (PDF) |
| 281 | Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma | 4.4 | 14 | Citations (PDF) |
| 282 | Promises and challenges of fluorescence cystoscopy | 1.9 | 11 | Citations (PDF) |
| 283 | Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer | 1.5 | 27 | Citations (PDF) |
| 284 | Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model | 1.9 | 26 | Citations (PDF) |
| 285 | Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort | 1.9 | 46 | Citations (PDF) |
| 286 | Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward | 1.9 | 12 | Citations (PDF) |
| 287 | Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target | 1.9 | 8 | Citations (PDF) |
| 288 | Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy | 1.9 | 31 | Citations (PDF) |
| 289 | Cost-Effectiveness in Minimally Invasive Urologic Surgery 2015, , 239-250 | | 1 | Citations (PDF) |
| 290 | Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study | 1.9 | 11 | Citations (PDF) |
| 291 | Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma | 1.5 | 27 | Citations (PDF) |
| 292 | ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms | 0.6 | 56 | Citations (PDF) |
| 293 | Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma | 1.6 | 10 | Citations (PDF) |
| 294 | TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma | 2.4 | 9 | Citations (PDF) |
| 295 | Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract | 4.4 | 39 | Citations (PDF) |
| 296 | Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results | 1.9 | 7 | Citations (PDF) |
| 297 | Adjuvant cisplatin‐based combined chemotherapy for lymph node (<scp>LN</scp>)‐positive urothelial carcinoma of the bladder (<scp>UCB</scp>) after radical cystectomy (<scp>RC</scp>): a retrospective international study of >1500 patients | 3.5 | 23 | Citations (PDF) |
| 298 | The role of adjuvant chemotherapy for lymph node‐positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study | 3.5 | 27 | Citations (PDF) |
| 299 | Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent | 2.4 | 3 | Citations (PDF) |
| 300 | Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? | 2.4 | 6 | Citations (PDF) |
| 301 | Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine | 2.5 | 97 | Citations (PDF) |
| 302 | Triglycerides in the Human Kidney Cortex: Relationship with Body Size | 2.5 | 61 | Citations (PDF) |
| 303 | Re: Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients | 1.4 | 0 | Citations (PDF) |
| 304 | Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy | 4.3 | 30 | Citations (PDF) |
| 305 | <scp>Ki67</scp> is an independent predictor of oncological outcomes in patients with localized clear‐cell renal cell carcinoma | 3.5 | 49 | Citations (PDF) |
| 306 | Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy | 3.5 | 35 | Citations (PDF) |
| 307 | Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer | 7.7 | 110 | Citations (PDF) |
| 308 | Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology? | 4.4 | 29 | Citations (PDF) |
| 309 | Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival | 1.9 | 22 | Citations (PDF) |
| 310 | Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: A contemporary review with focus on nonbilharzial squamous cell carcinoma | 1.9 | 21 | Citations (PDF) |
| 311 | Dysregulation of β-Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma | 4.4 | 18 | Citations (PDF) |
| 312 | Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis | 1.5 | 80 | Citations (PDF) |
| 313 | Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma | 4.4 | 33 | Citations (PDF) |
| 314 | Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma | 1.9 | 39 | Citations (PDF) |
| 315 | Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy | 1.9 | 24 | Citations (PDF) |
| 316 | Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients | 1.4 | 99 | Citations (PDF) |
| 317 | Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool | 1.4 | 134 | Citations (PDF) |
| 318 | What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up | 1.9 | 51 | Citations (PDF) |
| 319 | Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder | 1.9 | 31 | Citations (PDF) |
| 320 | The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease | 1.4 | 408 | Citations (PDF) |
| 321 | Urine markers for detection and surveillance of bladder cancer | 1.9 | 85 | Citations (PDF) |
| 322 | Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma | 1.4 | 23 | Citations (PDF) |
| 323 | Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract | 1.9 | 39 | Citations (PDF) |
| 324 | Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma | 1.5 | 15 | Citations (PDF) |
| 325 | Electrophysiological analysis of biopsy samples using elasticity as an inherent cell marker for cancer detection | 2.6 | 23 | Citations (PDF) |
| 326 | Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer? | 17.1 | 227 | Citations (PDF) |
| 327 | Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in 2030 | 1.4 | 250 | Citations (PDF) |
| 328 | Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity | 0.7 | 1 | Citations (PDF) |
| 329 | Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool | 1.4 | 23 | Citations (PDF) |
| 330 | Reply from Authors re: Suzanne Biehn Stewart, Shelby D. Reed, Judd W. Moul. Will the Future of Health Care Lead to the End of the Robotic Golden Years? Eur Urol 2014;65:325–7 | 1.4 | 0 | Citations (PDF) |
| 331 | Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer | 4.4 | 23 | Citations (PDF) |
| 332 | Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time | 1.4 | 125 | Citations (PDF) |
| 333 | Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses | 1.9 | 20 | Citations (PDF) |
| 334 | Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature | 1.9 | 27 | Citations (PDF) |
| 335 | Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? | 1.9 | 8 | Citations (PDF) |
| 336 | Prospective External Validation of a Bladder Cancer Detection Model | 4.4 | 33 | Citations (PDF) |
| 337 | Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer | 0.7 | 172 | Citations (PDF) |
| 338 | BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma | 4.4 | 67 | Citations (PDF) |
| 339 | Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review | 1.4 | 83 | Citations (PDF) |
| 340 | Capsule Commentary on Bassett et al., Gender, Race, and Variations in the Evaluation of Microscopic Hematuria Among Medicare Beneficiaries | 2.7 | 0 | Citations (PDF) |
| 341 | Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence? | 2.4 | 39 | Citations (PDF) |
| 342 | Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes | 16.3 | 302 | Citations (PDF) |
| 343 | Abstract B24: ATDC (Trim29) drives invasive bladder cancer formation 2014, , | | 0 | Citations (PDF) |
| 344 | Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy | 3.5 | 26 | Citations (PDF) |
| 345 | Systematic Review of Complications of Prostate Biopsy | 1.4 | 806 | Citations (PDF) |
| 346 | Metabolomic signatures of aggressive prostate cancer | 2.2 | 111 | Citations (PDF) |
| 347 | A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate CancerCell, 2013, 154, 1074-1084 | 35.1 | 246 | Citations (PDF) |
| 348 | Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy | 4.4 | 37 | Citations (PDF) |
| 349 | Comprehensive handbook for developing a bladder cancer cystectomy database | 1.9 | 7 | Citations (PDF) |
| 350 | Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma | 4.4 | 22 | Citations (PDF) |
| 351 | Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma | 1.5 | 32 | Citations (PDF) |
| 352 | Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy | 1.4 | 49 | Citations (PDF) |
| 353 | ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers | 1.4 | 211 | Citations (PDF) |
| 354 | Epidemiology and Risk Factors of Urothelial Bladder Cancer | 1.4 | 1,565 | Citations (PDF) |
| 355 | Predictors of cancer‐specific mortality after disease recurrence following radical cystectomy | 3.5 | 74 | Citations (PDF) |
| 356 | Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer | 1.4 | 4 | Citations (PDF) |
| 357 | Reduction in Hospital Admission Rates Due to Post-Prostate Biopsy Infections After Augmenting Standard Antibiotic Prophylaxis | 4.4 | 80 | Citations (PDF) |
| 358 | Cost-Effectiveness of Fluorescence In Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma | 4.4 | 31 | Citations (PDF) |
| 359 | Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy | 3.3 | 157 | Citations (PDF) |
| 360 | How Much is a Kidney Worth? Cost-Effectiveness of Routine Imaging After Ureteroscopy to Prevent Silent Obstruction | 4.4 | 20 | Citations (PDF) |
| 361 | Controlling Health Care Costs for Prostate Cancer | 1.4 | 2 | Citations (PDF) |
| 362 | Summary of the 6th annual bladder cancer think tank: New directions in urologic research | 1.9 | 6 | Citations (PDF) |
| 363 | Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy | 1.4 | 104 | Citations (PDF) |
| 364 | Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis | 1.4 | 60 | Citations (PDF) |
| 365 | Urinary cytology for the detection of urothelial carcinoma of the bladder—a flawed adjunct to cystoscopy? | 1.9 | 14 | Citations (PDF) |
| 366 | Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost‐effectiveness analysis | 3.5 | 36 | Citations (PDF) |
| 367 | Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives | 1.4 | 65 | Citations (PDF) |
| 368 | Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy | 1.4 | 62 | Citations (PDF) |
| 369 | Effect of statin use on outcomes of non‐muscle‐invasive bladder cancer | 3.5 | 27 | Citations (PDF) |
| 370 | Impact of fluid intake in the prevention of urinary system diseases | 2.4 | 54 | Citations (PDF) |
| 371 | Pathogenesis and Cost-Effectiveness of Preventing Kidney Stones | 0.7 | 0 | Citations (PDF) |
| 372 | Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy? | 3.5 | 1 | Citations (PDF) |
| 373 | Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro‐ureterectomy | 3.5 | 126 | Citations (PDF) |
| 374 | Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage <scp>T</scp>1 disease and negative lymph nodes after radical cystectomy | 3.5 | 57 | Citations (PDF) |
| 375 | From genomics to imaging—advances along the care continuum | 3.9 | 0 | Citations (PDF) |
| 376 | Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines | 2.1 | 50 | Citations (PDF) |
| 377 | Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer | 3.5 | 77 | Citations (PDF) |
| 378 | Is robotic surgery cost-effective | 2.1 | 49 | Citations (PDF) |
| 379 | A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma | 13.1 | 153 | Citations (PDF) |
| 380 | Cost Comparison of Robot-Assisted and Laparoscopic Pyeloplasty | 3.0 | 23 | Citations (PDF) |
| 381 | Three differentiation states risk-stratify bladder cancer into distinct subtypes | 7.7 | 210 | Citations (PDF) |
| 382 | BAP1 loss defines a new class of renal cell carcinoma | 16.3 | 759 | Citations (PDF) |
| 383 | Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery | 1.4 | 94 | Citations (PDF) |
| 384 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 385 | Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers | 4.4 | 38 | Citations (PDF) |
| 386 | Evaluation of Vitamin E and Selenium Supplementation for the Prevention of Bladder Cancer in SWOG Coordinated SELECT | 4.4 | 41 | Citations (PDF) |
| 387 | Cost-Effectiveness of Fluorescent Cystoscopy for Noninvasive Papillary Tumors | 4.4 | 2 | Citations (PDF) |
| 388 | 12th Annual Meeting of the Society of Urologic Oncology (SUO) Bladder Cancer Sessions I and II summary report | 1.9 | 4 | Citations (PDF) |
| 389 | Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy | 1.7 | 51 | Citations (PDF) |
| 390 | Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology | 1.9 | 24 | Citations (PDF) |
| 391 | Cost‐Effective Strategies for Management of Renal and Ureteral Calculi 2012, , 756-771 | | 0 | Citations (PDF) |
| 392 | The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria | 4.4 | 0 | Citations (PDF) |
| 393 | Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes | 2.8 | 47 | Citations (PDF) |
| 394 | The Challenges of Harnessing New Technology | 1.4 | 1 | Citations (PDF) |
| 395 | Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma | 1.4 | 141 | Citations (PDF) |
| 396 | Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma | 1.4 | 16 | Citations (PDF) |
| 397 | Re: Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients with Early-stage Kidney Cancer | 1.4 | 0 | Citations (PDF) |
| 398 | Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial | 3.5 | 29 | Citations (PDF) |
| 399 | Cost‐effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)‐guided prostate biopsy prophylaxis | 3.5 | 39 | Citations (PDF) |
| 400 | Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder | 3.5 | 12 | Citations (PDF) |
| 401 | Reported use of intravesical therapy for non‐muscle‐invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey | 3.5 | 26 | Citations (PDF) |
| 402 | Primary prevention of nephrolithiasis is cost‐effective for a national healthcare system | 3.5 | 53 | Citations (PDF) |
| 403 | Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy | 1.7 | 25 | Citations (PDF) |
| 404 | Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy | 3.5 | 31 | Citations (PDF) |
| 405 | Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder | 4.4 | 7 | Citations (PDF) |
| 406 | Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy | 4.4 | 31 | Citations (PDF) |
| 407 | Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer | 4.4 | 84 | Citations (PDF) |
| 408 | Cost Comparison of Robotic, Laparoscopic, and Open Partial Nephrectomy | 3.0 | 105 | Citations (PDF) |
| 409 | Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression | 0.6 | 158 | Citations (PDF) |
| 410 | Expression of cell cycle–related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder☆ | 2.4 | 22 | Citations (PDF) |
| 411 | Editorial Comment | 1.5 | 0 | Citations (PDF) |
| 412 | Predictors of costs for robotic-assisted laparoscopic radical prostatectomy | 1.9 | 15 | Citations (PDF) |
| 413 | Practice Variation in the Surgical Management of Urinary Lithiasis | 4.4 | 59 | Citations (PDF) |
| 414 | Cost-Effectiveness of Primary Prevention Strategies for Nephrolithiasis | 4.4 | 33 | Citations (PDF) |
| 415 | Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation | 2.4 | 3 | Citations (PDF) |
| 416 | Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer | 2.9 | 62 | Citations (PDF) |
| 417 | Bilharzial vs non‐bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase‐2 expression | 3.5 | 25 | Citations (PDF) |
| 418 | Upper urinary tract urothelial carcinoma with loco‐regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration | 3.5 | 68 | Citations (PDF) |
| 419 | Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non–Muscle-Invasive Bladder Cancer | 1.4 | 50 | Citations (PDF) |
| 420 | Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer | 4.4 | 126 | Citations (PDF) |
| 421 | Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments | 0.9 | 119 | Citations (PDF) |
| 422 | Primary Adenocarcinoma of the Urinary Bladder | 0.6 | 20 | Citations (PDF) |
| 423 | Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated Prostate Specific Antigen | 1.1 | 9 | Citations (PDF) |
| 424 | Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma | 2.9 | 99 | Citations (PDF) |
| 425 | Cost–effectiveness of robotic-assisted laparoscopic procedures in urologic surgery in the USA | 2.2 | 18 | Citations (PDF) |
| 426 | Economics of Bladder Cancer Diagnosis and Surveillance 2011, , 121-137 | | 0 | Citations (PDF) |
| 427 | AUAP-3 Urothelial carcinoma at the uretero-enteric junction : multi-center evaluation of oncologic outcomes after radical nephroureterctomy | 0.1 | 0 | Citations (PDF) |
| 428 | Economics of robotics in urology | 2.1 | 35 | Citations (PDF) |
| 429 | The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons | 3.5 | 39 | Citations (PDF) |
| 430 | Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy | 1.4 | 151 | Citations (PDF) |
| 431 | Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort | 1.4 | 155 | Citations (PDF) |
| 432 | Cost Comparison of Robotic, Laparoscopic, and Open Radical Prostatectomy for Prostate Cancer | 1.4 | 227 | Citations (PDF) |
| 433 | Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome | 1.4 | 49 | Citations (PDF) |
| 434 | Re: Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy And Tolerance | 1.4 | 0 | Citations (PDF) |
| 435 | High‐risk patients with hematuria are not evaluated according to guideline recommendations | 4.4 | 65 | Citations (PDF) |
| 436 | p53 expression in patients with advanced urothelial cancer of the urinary bladder | 3.5 | 60 | Citations (PDF) |
| 437 | Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder | 3.5 | 72 | Citations (PDF) |
| 438 | International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy | 3.5 | 129 | Citations (PDF) |
| 439 | The influence of body mass index on the cost of radical prostatectomy for prostate cancer | 3.5 | 11 | Citations (PDF) |
| 440 | Transitional research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers | 4.3 | 22 | Citations (PDF) |
| 441 | Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients | 4.4 | 52 | Citations (PDF) |
| 442 | Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer | 4.4 | 128 | Citations (PDF) |
| 443 | Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management | 4.4 | 48 | Citations (PDF) |
| 444 | Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder | 4.4 | 88 | Citations (PDF) |
| 445 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 446 | Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients | 4.4 | 62 | Citations (PDF) |
| 447 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 448 | Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma | 4.4 | 214 | Citations (PDF) |
| 449 | Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients | 4.4 | 174 | Citations (PDF) |
| 450 | Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract | 4.4 | 174 | Citations (PDF) |
| 451 | Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey | 1.9 | 74 | Citations (PDF) |
| 452 | Role of biomarkers to predict outcomes and response to therapy | 1.9 | 6 | Citations (PDF) |
| 453 | BCAN Think Tank session 2: Molecular detection of bladder cancer: The path to progress | 1.9 | 3 | Citations (PDF) |
| 454 | Considerations on implementing diagnostic markers into clinical decision making in bladder cancer | 1.9 | 89 | Citations (PDF) |
| 455 | Statistical consideration for clinical biomarker research in bladder cancer | 1.9 | 109 | Citations (PDF) |
| 456 | Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival | 3.5 | 25 | Citations (PDF) |
| 457 | Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients | 4.4 | 65 | Citations (PDF) |
| 458 | Mesh kits for anterior vaginal prolapse are not cost effective | 1.4 | 11 | Citations (PDF) |
| 459 | Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones | 0.4 | 46 | Citations (PDF) |
| 460 | Urothelial Bladder Cancer: Screening with Urine-Based Tumor Markers 2010, , 196-209 | | 0 | Citations (PDF) |
| 461 | Understanding Concepts Related to Health Economics in Urology 2010, , 45-49 | | 0 | Citations (PDF) |
| 462 | Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer | 5.1 | 131 | Citations (PDF) |
| 463 | Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study | 6.4 | 61 | Citations (PDF) |
| 464 | Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma | 17.1 | 251 | Citations (PDF) |
| 465 | Prostate cancer biomarker discovery using high performance mass spectral serum profiling | 5.5 | 16 | Citations (PDF) |
| 466 | Decision Making in the Management of Renal Cell Carcinoma: Can Nomograms Assist? | 1.4 | 3 | Citations (PDF) |
| 467 | Re: Evaluating the Learning Curve for Robot-Assisted Laparoscopic Radical Cystectomy | 1.4 | 0 | Citations (PDF) |
| 468 | Editorial Comment on: Serum Proteomic Profiling in Patients with Bladder Cancer | 1.4 | 1 | Citations (PDF) |
| 469 | Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy | 1.4 | 573 | Citations (PDF) |
| 470 | Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration | 4.4 | 925 | Citations (PDF) |
| 471 | Key concerns about the current state of bladder cancer | 4.4 | 52 | Citations (PDF) |
| 472 | Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi‐institutional analysis of 1363 patients | 3.5 | 152 | Citations (PDF) |
| 473 | Impact of body mass index on clinical and cost outcomes after radical cystectomy | 3.5 | 17 | Citations (PDF) |
| 474 | Impact of clinical factors, including a point‐of‐care nuclear matrix protein‐22 assay and cytology, on bladder cancer detection | 3.5 | 56 | Citations (PDF) |
| 475 | Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome | 3.5 | 32 | Citations (PDF) |
| 476 | Editorial Comment | 4.4 | 22 | Citations (PDF) |
| 477 | General Anesthesia and Contrast-Enhanced Computed Tomography to Optimize Renal Percutaneous Radiofrequency Ablation: Multi-Institutional Intermediate-Term Results | 3.0 | 56 | Citations (PDF) |
| 478 | Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement | 4.4 | 32 | Citations (PDF) |
| 479 | Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy | 4.4 | 32 | Citations (PDF) |
| 480 | Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy | 4.4 | 82 | Citations (PDF) |
| 481 | Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker | 4.4 | 71 | Citations (PDF) |
| 482 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 483 | p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy | 4.4 | 49 | Citations (PDF) |
| 484 | Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer | 4.4 | 13 | Citations (PDF) |
| 485 | How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease | 4.4 | 34 | Citations (PDF) |
| 486 | Economics and Cost of Care of Stone Disease | 2.0 | 124 | Citations (PDF) |
| 487 | Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival | 3.5 | 24 | Citations (PDF) |
| 488 | Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours | 3.5 | 31 | Citations (PDF) |
| 489 | Is there a rationale for bladder cancer screening? | 2.8 | 6 | Citations (PDF) |
| 490 | Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy | 4.4 | 165 | Citations (PDF) |
| 491 | Cost‐effectiveness of prostate cancer chemoprevention | 4.4 | 51 | Citations (PDF) |
| 492 | The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses | 4.4 | 16 | Citations (PDF) |
| 493 | Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection | 3.5 | 34 | Citations (PDF) |
| 494 | Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study | 3.5 | 16 | Citations (PDF) |
| 495 | Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery | 3.5 | 76 | Citations (PDF) |
| 496 | Predicting survival after radical cystectomy for bladder cancer | 3.5 | 46 | Citations (PDF) |
| 497 | Urothelial bladder cancer: biomarkers for detection and screening | 3.5 | 19 | Citations (PDF) |
| 498 | Editorial Comment on: Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder | 1.4 | 1 | Citations (PDF) |
| 499 | Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones | 1.4 | 92 | Citations (PDF) |
| 500 | Nomograms for Bladder Cancer | 1.4 | 82 | Citations (PDF) |
| 501 | Reply to Peter L. Steinberg's Letter to the Editor re: Karim Bensalah, Margaret Pearle and Yair Lotan. Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones. Eur Urol 2008;53:411–9 | 1.4 | 0 | Citations (PDF) |
| 502 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 503 | Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy | 1.5 | 56 | Citations (PDF) |
| 504 | Are Urologists Fairly Reimbursed for Complex Procedures: Failure of 22 Modifier? | 1.5 | 18 | Citations (PDF) |
| 505 | Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy | 1.5 | 53 | Citations (PDF) |
| 506 | Determinants of Quality of Life for Patients With Kidney Stones | 4.4 | 99 | Citations (PDF) |
| 507 | Does Obesity Impact the Costs of Partial and Radical Nephrectomy? | 4.4 | 13 | Citations (PDF) |
| 508 | Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder | 4.4 | 64 | Citations (PDF) |
| 509 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 510 | Climate-related increase in the prevalence of urolithiasis in the United States | 7.7 | 294 | Citations (PDF) |
| 511 | Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection | 5.1 | 59 | Citations (PDF) |
| 512 | Sirolimus in Metatastic Renal Cell Carcinoma | 17.1 | 13 | Citations (PDF) |
| 513 | Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: A promising strategy? | 4.3 | 5 | Citations (PDF) |
| 514 | Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use | 1.7 | 28 | Citations (PDF) |
| 515 | Cost–effectiveness of bladder cancer screening | 1.6 | 2 | Citations (PDF) |
| 516 | Bladder Cancer Screening and Future Directions in Urine-Based Markers for Bladder Urothelial Carcinoma | 1.1 | 0 | Citations (PDF) |
| 517 | Laparoscopic and Open Partial Nephrectomy: Cost Comparison with Analysis of Individual Parameters | 3.0 | 14 | Citations (PDF) |
| 518 | Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols? | 0.9 | 0 | Citations (PDF) |
| 519 | Contemporary Laparoscopic and Open Radical Retropubic Prostatectomy: Pathologic Outcomes and Kattan Postoperative Nomograms Are Equivalent | 1.5 | 7 | Citations (PDF) |
| 520 | In Vitro Assessment of the Efficacy of Thermal Therapy in Human Renal Cell Carcinoma | 1.5 | 22 | Citations (PDF) |
| 521 | Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts | 1.9 | 28 | Citations (PDF) |
| 522 | Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder | 1.9 | 37 | Citations (PDF) |
| 523 | Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome | 2.4 | 71 | Citations (PDF) |
| 524 | Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy | 21.9 | 181 | Citations (PDF) |
| 525 | Efficacy of Laser-Activated Gold Nanoshells in Ablating Prostate Cancer Cells in Vitro | 3.0 | 93 | Citations (PDF) |
| 526 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 527 | Editorial Comment | 4.4 | 1 | Citations (PDF) |
| 528 | Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma | 4.4 | 116 | Citations (PDF) |
| 529 | Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder | 4.4 | 39 | Citations (PDF) |
| 530 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 531 | Editorial Comment | 4.4 | 0 | Citations (PDF) |
| 532 | Economics of Stone Management | 2.1 | 58 | Citations (PDF) |
| 533 | Survivin expression is associated with bladder cancer presence, stage, progression, and mortality | 4.4 | 128 | Citations (PDF) |
| 534 | Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness | 5.0 | 117 | Citations (PDF) |
| 535 | Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours | 3.5 | 123 | Citations (PDF) |
| 536 | A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome | 3.5 | 54 | Citations (PDF) |
| 537 | Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy | 1.4 | 301 | Citations (PDF) |
| 538 | Re: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States | 1.4 | 0 | Citations (PDF) |
| 539 | Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy | 1.4 | 145 | Citations (PDF) |
| 540 | Survivin: a promising biomarker for detection and prognosis of bladder cancer | 2.4 | 87 | Citations (PDF) |
| 541 | Screening for bladder cancer: a perspective | 2.4 | 44 | Citations (PDF) |
| 542 | Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium | 4.4 | 590 | Citations (PDF) |
| 543 | Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | 4.4 | 176 | Citations (PDF) |
| 544 | Cancer Specific Outcomes in Patients With PT0 Disease Following Radical Cystectomy | 4.4 | 46 | Citations (PDF) |
| 545 | Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model | 4.4 | 28 | Citations (PDF) |
| 546 | Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder | 4.4 | 148 | Citations (PDF) |
| 547 | Editorial comment | 4.4 | 32 | Citations (PDF) |
| 548 | Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis | 2.4 | 81 | Citations (PDF) |
| 549 | Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy | 1.5 | 27 | Citations (PDF) |
| 550 | Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis | 1.9 | 41 | Citations (PDF) |
| 551 | Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis | 1.9 | 2 | Citations (PDF) |
| 552 | Novel blood biomarkers of human urinary bladder cancer | 1.9 | 2 | Citations (PDF) |
| 553 | A survivin gene signature predicts aggressive tumor behavior | 1.9 | 0 | Citations (PDF) |
| 554 | Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer | 1.1 | 0 | Citations (PDF) |
| 555 | Against the motion | 1.4 | 1 | Citations (PDF) |
| 556 | For the motion | 1.4 | 5 | Citations (PDF) |
| 557 | Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model | 1.4 | 70 | Citations (PDF) |
| 558 | Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage | 1.4 | 143 | Citations (PDF) |
| 559 | Soluble Fas—A promising novel urinary marker for the detection of recurrent superficial bladder cancer | 4.4 | 50 | Citations (PDF) |
| 560 | Should we screen for bladder cancer in a high-risk population? | 4.4 | 111 | Citations (PDF) |
| 561 | Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy | 6.4 | 217 | Citations (PDF) |
| 562 | Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease | 6.4 | 130 | Citations (PDF) |
| 563 | Radiofrequency Ablation of Renal Tumors: Intermediate-Term Results | 3.0 | 124 | Citations (PDF) |
| 564 | The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model | 0.9 | 25 | Citations (PDF) |
| 565 | The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population | 3.5 | 41 | Citations (PDF) |
| 566 | A cost comparison of nephron-sparing surgical techniques for renal tumour | 3.5 | 54 | Citations (PDF) |
| 567 | International comparison of cost effectiveness of medical management strategies for nephrolithiasis | 0.4 | 59 | Citations (PDF) |
| 568 | Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes | 17.1 | 30 | Citations (PDF) |
| 569 | Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy | 17.1 | 275 | Citations (PDF) |
| 570 | NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER | 4.4 | 141 | Citations (PDF) |
| 571 | Economics of Stone Management | 1.1 | 3 | Citations (PDF) |
| 572 | Conservative management of priapism in acute spinal cord injury | 1.5 | 19 | Citations (PDF) |
| 573 | Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard? | 1.5 | 26 | Citations (PDF) |
| 574 | Cost comparison of laparoscopic versus radical retropubic prostatectomy | 1.5 | 33 | Citations (PDF) |
| 575 | Retinoic Acid Receptor β2 Hypermethylation | 6.4 | 7 | Citations (PDF) |
| 576 | THE PERCENT OF BIOPSY CORES POSITIVE FOR CANCER IS A PREDICTOR OF ADVANCED PATHOLOGICAL STAGE AND POOR CLINICAL OUTCOMES IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY | 4.4 | 42 | Citations (PDF) |
| 577 | COST-EFFECTIVENESS OF MEDICAL MANAGEMENT STRATEGIES FOR NEPHROLITHIASIS | 4.4 | 79 | Citations (PDF) |
| 578 | THE VALUE OF YOUR TIME: EVALUATION OF EFFECTS OF CHANGES IN MEDICARE REIMBURSEMENT RATES ON THE PRACTICE OF UROLOGY | 4.4 | 45 | Citations (PDF) |
| 579 | THE NEW ECONOMICS OF RADICAL PROSTATECTOMY: COST COMPARISON OF OPEN, LAPAROSCOPIC AND ROBOT ASSISTED TECHNIQUES | 4.4 | 239 | Citations (PDF) |
| 580 | Cost-Effective Treatment for Ureteropelvic Junction Obstruction: A Decision Tree Analysis | 4.4 | 29 | Citations (PDF) |
| 581 | Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses | 1.5 | 400 | Citations (PDF) |
| 582 | Histopathology of surgically managed renal tumors: analysis of a contemporary series | 1.5 | 136 | Citations (PDF) |
| 583 | Factors influencing the outcomes of penile prosthesis surgery at a teaching institution | 1.5 | 98 | Citations (PDF) |
| 584 | Cost Comparison of Hand Assisted Laparoscopic Nephrectomy and Open Nephrectomy: Analysis of Individual Parameters | 4.4 | 20 | Citations (PDF) |
| 585 | Clinical Use of the Holmium:YAG Laser in Laparoscopic Partial Nephrectomy | 3.0 | 65 | Citations (PDF) |
| 586 | Radiofrequency Coagulation of Renal Parenchyma: Comparison of Effects of Energy Generators on Treatment Efficacy | 3.0 | 40 | Citations (PDF) |
| 587 | Laparoscopic Interstitial Laser Coagulation of Renal Tissue with and without Hilar Occlusion in the Porcine Model | 3.0 | 14 | Citations (PDF) |
| 588 | Laparoscopic Partial Nephrectomy with a Diode Laser: Porcine Results | 3.0 | 45 | Citations (PDF) |
| 589 | Transvaginal laparoscopic nephrectomy: development and feasibility in the porcine model | 1.5 | 229 | Citations (PDF) |
| 590 | Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters | 1.5 | 27 | Citations (PDF) |
| 591 | Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost Analysis | 4.4 | 21 | Citations (PDF) |
| 592 | Management Of Ureteral Calculi: A Cost Comparison And Decision Making Analysis | 4.4 | 158 | Citations (PDF) |
| 593 | COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A DECISION ANALYTICAL APPROACH | 4.4 | 90 | Citations (PDF) |
| 594 | Differential Expression of Nuclear Retinoid Receptors in Normal and Malignant Prostates | 17.1 | 66 | Citations (PDF) |
